Navigation Links
DuoCort AB: DuoCort announces Phase I Data Presentation at the,European Congress of Endocrinology

HELSINGBORG, Sweden--(BUSINESS WIRE)--Apr 25, 2007 - DuoCort AB today announced that results of the Phase I trial of its 5 mg and 20 mg dual release hydrocortisone tablets for adrenal insufficiency will be presented at the 9th European Congress of Endocrinology on April 30 in Budapest. The trial evaluated the safety and pharmacokinetics of the new hydrocortisone tablets in healthy volunteers.

The Phase I study showed that both the DuoCort 5 mg and 20 mg hydrocortisone dual-release tablets were safe and well tolerated. The novel dual-release formulation showed a rapid increase in cortisol levels after single-dose administration, the dose was well absorbed and it had similar bioavailability to the oral hydrocortisone in the literature. Moreover, the data showed no risk of dose accumulation. The release profile closely resembled the physiological one, including the natural nocturnal cortisol free interval.

Based on the promising Phase I data, DuoCort is now launching its Phase II / III program. "We are very pleased with the outcome of the Phase I trial, especially as there was very little inter- or intra-individual variability in the pharmacokinetics and the drug release profiles look very like the physiological release profile of cortisol in healthy individuals," said DuoCort's Chief Medical Officer, Dr Gudmundur Johannsson. "The Phase II trial will seek to demonstrate similar safety, tolerability and pharmacokinetics in patients, as well as gathering other safety and quality of life data."

About dual-release hydrocortisone

DuoCort's dual-release 5 mg and 20 mg hydrocortisone tablets for patients with chronic adrenal insufficiency were granted an Orphan Medicinal Product Designation in the European Union in May 2006. DuoCort's objective is to improve today's glucocorticoid replacement therapy with a once-daily tablet which is more convenient than current treatment and capable of improving pat
'"/>




Page: 1 2

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:9/2/2015)... 2, 2015 Demers Ambulances is proud to announce ... new dealer for the states of Mississippi ... . "This will enable Demers to ... Lafortune , Executive Vice-President for Demers Ambulances. "Emergency Equipment Professionals ... and Alabama , giving them a ...
(Date:9/2/2015)... BOCA RATON, Fla. , Sept. 2, 2015 ... Cartledge , MD, FACS, has begun performing ultra-minimally ... patients who are on anticoagulants such as Coumadin, ... of Cardiothoracic Surgery at the Hospital, is one ... this method, which involves making two microscopic incisions ...
(Date:9/2/2015)... -- Aethlon Medical, Inc. (Nasdaq: AEMD ), today announced that ... at the Rodman & Renshaw 17th Annual Global Investment Conference ... a.m. ET on Thursday, September 10, 2015. The ... audio webcast which can be accessed by visiting the investor ... . The webcast will be archived for thirty days.  ...
Breaking Medicine Technology:Demers Ambulances has named Emergency Equipment Professionals (EEP) Inc. as their dealer for the states of MS, AL and TN 2Boca Regional Introduces Ultra-Minimally Invasive Surgical Procedure for Atrial Fibrillation Patients 2Boca Regional Introduces Ultra-Minimally Invasive Surgical Procedure for Atrial Fibrillation Patients 3
... Texas, March 15, 2011 Argon Medical Devices, Inc. ... license agreement with Rex Medical, LP ("Rex Medical") for exclusive ... Vena Cava Filter, an implantable device used in the prevention ... with the addition of Option™ to our product portfolio. This ...
... March 15, 2011 OncoSec Medical Inc. (OTC Bulletin ... and proprietary medical approaches to treat solid tumor cancers ... signed an agreement with Inovio Pharmaceuticals, Inc. (NYSE Amex: ... OncoSec of certain non-DNA vaccine technology and intellectual property ...
Cached Medicine Technology:Argon Medical Devices Announces Exclusive License and Distribution Agreement for Option™ Retrievable Inferior Vena Cava Filter 2Argon Medical Devices Announces Exclusive License and Distribution Agreement for Option™ Retrievable Inferior Vena Cava Filter 3OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals 2OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals 3OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals 4
(Date:9/2/2015)... ... September 02, 2015 , ... ERT, a ... cloud analytics and workflow solutions today announced the September 2015 installments to ... participate in interactive programs in which ERT scientists and partner subject matter ...
(Date:9/2/2015)... ... September 02, 2015 , ... Density ... or final products. Automating sample handling makes density measurements more efficient and error-free. ... step of the automated workflow and the advantages compared to manual sample handling. ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... food banks in commemorating “Hunger Action Month” during the entire month of September. ... Food Bank will be dedicating its efforts this September to an awareness campaign ...
(Date:9/2/2015)... WI (PRWEB) , ... September 02, 2015 , ... ... Cypress Benefit Administrators is taking action after seeing a significant increase ... TPA’s Argus Claim Review division has found many cases of OON ASCs encouraging ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... patented products, announces Hand Free Pocket Cop, a safety invention that protects people ... US is worth $31 billion," says Scott Cooper, CEO and Creative Director of ...
Breaking Medicine News(10 mins):Health News:ERT Announces Web Seminar Series on Optimizing Trial Data Collection & Gaining Real-Time Data Insights 2Health News:ERT Announces Web Seminar Series on Optimizing Trial Data Collection & Gaining Real-Time Data Insights 3Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 2Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 3Health News:#IfOnlyYouKnew: Alameda County Community Food Bank Commemorates September as National Hunger Action Month 2Health News:#IfOnlyYouKnew: Alameda County Community Food Bank Commemorates September as National Hunger Action Month 3Health News:#IfOnlyYouKnew: Alameda County Community Food Bank Commemorates September as National Hunger Action Month 4Health News:TPA Cracks Down on Forbidden Tactics Used by Out-of-Network Surgical Centers 2Health News:TPA Cracks Down on Forbidden Tactics Used by Out-of-Network Surgical Centers 3Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 2Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 3Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 4Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 5Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 6Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 7
... a history of sexual abuse, regardless of the ... correlates strongly with a lifetime diagnosis of multiple ... of Mayo Clinic Proceedings ( http://www.mayoclinicproceedings.com/ ), ... is associated with suicide attempts, post-traumatic stress disorder, ...
... Institute of Allergy and Infectious Diseases (NIAID), part of ... Western Reserve University School of Medicine as the lead ... Research (ICEMR). The $7.9M seven-year grant will accelerate the ... prestigious center is one of ten new malaria research ...
... Drinking tart cherry juice daily could help reduce the ... sleep, according to a new study published in the ... of University of Pennsylvania, University of Rochester and VA Center ... habits of 15 older adults. The adults drank 8 ounces ...
... -- Lowly bacteria are turning out to be much more ... of the journal Molecular Microbiology , Loyola University Health ... acetylation," which once was thought to be rare in bacteria. ... has led to the "dawning of a new age" in ...
... from a healthy donor (allogeneic) offers the chance of ... lymphocytic leukemia (CLL), irrespective of genetic prognostic factors and ... Study Group proved this in a multicentric clinical phase ... consultant and head of the division of stem cell ...
... By Dennis Thompson HealthDay Reporter , SUNDAY, July 11 ... expected to lead to an increase in cases of glaucoma, the ... A number of demographic and health trends have increased the number ... These trends include: The aging of America , Growth ...
Cached Medicine News:Health News:Mayo Clinic Proceedings: Sexual abuse survivors have increased of psychiatric disorders 2Health News:Case Western Reserve University named International Center of Excellence for Malaria Research 2Health News:Case Western Reserve University named International Center of Excellence for Malaria Research 3Health News:New study suggests tart cherry juice can be a natural solution for insomnia 2Health News:'Dawning of a new age' in bacteria research 2Health News:Stem cell transplantation of therapy-resistant chronic leukemia successful 2Health News:Glaucoma Cases on the Rise in U.S. 2Health News:Glaucoma Cases on the Rise in U.S. 3
... System RCS 800 closes various plastic primary and ... way. Different tube heights and diameters can be ... be used for send-outs. The integration into other ... System RSD 800 and High Throughput Sorter RSD ...
... Decapping System DS 800 selectively removes closures from ... the barcode towards the rack opening in one ... integrated in PVT Systems like Sorting System RS ... Sorter RSD ProVolume and Aliquoting System RSD 800A. ...
... Nanogen offers reagents to detect ... human parainfluenza virus 1, 2 and ... and respiratory syncytial virus A and ... reagents to create homebrew tests., ...
... Alert Detection Reagents provide molecular labs a ... assays. By using our MGB technology, combined ... is now able to provide molecular labs ... sequences of specific organisms or genetic mutations ...
Medicine Products: